Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Switzerland / NCT06250582
Recruiting Not applicable

Does Virtual Reality Improve Symptom Burden in Dialysis Patients?

NCT06250582 · tracked via the Priya Life Science Switzerland tracker
Sponsor
David Blum
Phase
Not applicable
Started
2024-12-02
Last updated
2025-04-27

Condition(s) studied

DialysisVirtual Reality

Investigational drug(s) / intervention(s)

virtual reality therapy

virtual reality therapy: A virtual reality therapy will be applied for 30 minutes. Patients will be wearing the glasses while lying in bed/chair during their regular dialysis session. Vital signs will be monitored repeatedly. At defined times, patients are asked to answer various questionnaires about their physical and mental health.

Study summary

The goal of this clinical trial is to investigate the use of virtual reality therapy in dialysis patients. The main question it aims to answer is: Does virtual reality improve symptom burden in dialysis patients and improve their mental wellbeing? Over a period of one month, one virtual reality therapy session of 30 minutes will be performed during each regular hemodialysis session. Since we will conduct a monocentric, crossover randomized controlled trial, the participants act as their own control group.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Older than 18 years; * in treatment with thrice-weekly hemodialysis sessions; * regular hemodialysis duration of three to five hours * having no visual impairment * having no acoustic deficit * patient must be capable of speaking and understanding German or English * no signs of cognitive impairment * patient oriented in time and space * being able to give informed consent as documented by signature Exclusion Criteria: * diagnosis of epilepsy * current pregnancy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Hospital Zurich Zurich Canton of Zurich Recruiting

More David Blum trials in Switzerland

DigiPall; a Trial of Digital Patient Reported Outcome and Biomarker Monitoring in Palliative Care Recruiting

Other trials for the same condition

Virtual Reality Training for Laparoscopic Cholecystectomy Recruiting
Effect of Virtual Reality on Patient's Comfort During Cardiac Electronic Device Implantation. Recruiting
Effect of Virtual Reality on the Need of Premedication Before Surgery Recruiting
Restorative Environments for Gait Therapy with VR Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06250582 on ClinicalTrials.gov ↗ ← All trials in Switzerland